KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Stress Ulcer Prophylaxis May Not Prevent Gastrointestinal Bleeding in Neonates December 4, 2023According to a poster presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition, stress ulcer prophylaxis (SUP) did not increase adverse effects, suggesting limited preventive benefits for gastrointestinal bleeding (GIB) in neonates.
- Slideshow: Evaluating Perioperative Opioid Use and Analgesic Options December 4, 2023Three poster presented at the ASHP Midyear Clinical Meeting delved deeper into perioperative pain management.
- Instagram Could Serve as Educational Platform for New FDA Drug Approvals December 4, 2023An evaluative study on an open resource Instagram page that provides information on new medications to pharmacists was recently presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition.
- Navigating the Oncology Specialty Patient Journey December 4, 2023In this conversation from HAS 2023, Randy Falkenrath demystifies the oncology medication management model and explains how specialty pharmacist can help patients access care.
- Examining Barriers to Reproductive Care for Women with Disabilities December 1, 2023The risks of poor health, more health care needs, and gynecological cancer are significantly increased in patients with disabilities.
- Continuous Glucose Monitors May Help Alleviate Care Burden for Parents of Young Children with T1D December 1, 2023A new study found that glucose monitoring devices can help significantly improve the sleep of both parents and children.
- The Importance of Pharmacists in Care Teams for Pregnant People with Diabetes December 1, 2023A Q&A with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, director of education and training in diabetes technology at the Cleveland Clinic.
- Antiseizure Medications Linked to Serious Potential Reaction, FDA Warns November 30, 2023Levetiracetam and clobazam can cause Drug Reaction with Eosinophilia and Systemic Symptoms, which can start as a rash but progress quickly, potentially resulting in injury to internal organs, hospitalization, and death.
- Pharmacists in California Stop Flavoring Medication for Children Due to New Rules November 30, 2023Federal guidance from the United States Pharmacopeia characterizes the practice as drug compounding, which pharmacists fear may drive up prices.
- Examining Barriers to Care in Diabetic Retinopathy Screening November 30, 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.
Pharmacy Times articles
- Novel Technology Could Reduce Weight Control Drug Injections for Patients With Diabetes December 4, 2023A new hydrogel drug delivery system could change the way diabetes is managed.
- Reduced Structural Stigma Against Sexual Minorities Is Associated With Greater Rates of Male PrEP Prescriptions December 4, 2023The study authors note that additional policies to reduce structural stigma against sexual minorities could continue to improve the rate of individuals who initiate PrEP use.
- FDA Approves Pirtobrutinib For Treatment of Adult Patients With CLL, SLL December 4, 2023Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.
- Study: Substantial Deficiencies in Capture of Cognitive Safety in Drug Trials December 4, 2023Despite nearly one-third of reversible dementia cases being drug induced, cognitive safety is a neglected aspect of clinical trials.
- Migraine Medication Could Be More Effective Than Ibuprofen for Treatment of Attacks December 4, 2023Three classes of drugs could be 2 to 5 times more effective than ibuprofen for the treatment of migraine attacks, according to results of a study.
- Survey Finds Individuals Worried About Infection During Upcoming "Tripledemic" December 4, 2023Fewer individuals have received the flu shot this season, compared to previous years.
- Certain Personality Traits May Lower the Risk of Developing Dementia December 4, 2023Although personality was linked to cognitive performance on tests, it was not linked to dementia pathophysiology.
- Radiation Therapy Could Potentially Improve Heart Function for Heart Failure December 4, 2023In mice with heart failure, radiation therapy demonstrated improved heart function, specifically in the left ventricle, and reduced inflammation in the heart.
- Medicare Part D Claims Have Increased, But 340B Prescriptions Increased Faster December 4, 2023The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2013 to 19.3% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% to 49.9%.
- Pharmacist-Prescribing Intervention Leads to Cost-Effective Savings in Blood Pressure Care December 4, 2023The study authors reported a 50% uptick in pharmacist prescribing was associated with approximately $1.137 trillion in savings over a 30-year time period.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com